Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia
Article content
BOSTON & SYDNEY — Berkshire Hathaway Specialty Insurance (BHSI) today announced the introduction of a Management Liability Insurance Policy tailored expressly for Life Science, BioTech and Pharmaceutical (LBP) companies in Australia.
Article content
'The new LBP Management Liability Policy reflects our commitment to Australia's thriving life sciences community and our deep understanding of the challenges start-ups face at every stage of their journey,' said Jessica Jefferies, Underwriting Manager, National Brokers, Executive & Professional Lines, BHSI Australia. 'Life Sciences is one of the most promising industries in Australia and we are thrilled to be able to provide an innovative solution to support the industry'.
Article content
BHSI's new LBP Management Liability Insurance Policy is specifically for the R&D ecosystem – all stakeholders in Australia's diverse and energetic life sciences sector.
The new product offers enhanced cover tailored for life sciences companies, with coverage not found in standard Management Liability policies. BHSI's solution will extend cover and ensure Directors, Officers, Scientific and Medical Advisory Boards all get the benefit of cover as they develop cutting-edge solutions globally. With an understanding of the funding requirements, the product provides two key elements of protection, extending cover for private capital raisings, and not excluding cover in the event of the Company's insolvency. With many Australian life sciences companies looking abroad for clinical development, BHSI's offering has the ability to extend protection to U.S. exposures, recognising the frequent pursuit of FDA approvals by Australian firms.
Article content
The new solution expands BHSI's existing Management Liability policy wording for private companies and not-for-profits.
Article content
BHSI is a leading market for Directors and Officers Liability insurance for ASX-listed life sciences companies in Australia. This launch extends that expertise and forms part of BHSI's strategy to provide tailored support for biotech and pharmaceutical customers from start-up to scale. To learn more, contact jessica.jefferies@bhspecialty.com.
Article content
Berkshire Hathaway Specialty Insurance Company (incorporated in Nebraska, USA) ABN 84 600 643 034, AFS Licence No. 466713 ( www.bhspecialty.com) provides commercial property, casualty, healthcare professional liability, executive and professional lines, transactional liability, surety, marine, travel, programs, accident & health, medical stop loss, homeowners, and multinational insurance. The actual and final terms of coverage for all product lines may vary. Berkshire Hathaway Specialty Insurance Company holds financial strength ratings of A++ from AM Best and AA+ from Standard & Poor's. Based in Boston, Berkshire Hathaway Specialty Insurance has offices in Atlanta, Boston, Chicago, Columbia, Dallas, Houston, Indianapolis, Irvine, Los Angeles, New York, Plymouth Meeting, San Francisco, San Ramon, Seattle, Stevens Point, Adelaide, Auckland, Barcelona, Brisbane, Brussels, Calgary, Cologne, Dubai, Dublin, Frankfurt, Hamburg, Hong Kong, Kuala Lumpur, London, Lyon, Macau, Madrid, Manchester, Melbourne, Milan, Munich, Paris, Perth, Singapore, Stockholm, Sydney, Toronto, and Zurich.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
6 hours ago
- Globe and Mail
Why Summit Therapeutics Stock Tanked Today
An analyst's downbeat new take on Summit Therapeutics (NASDAQ: SMMT) pushed its stock downward on Hump Day. At the end of Wednesday, the shares had booked a loss of over 11% in price as investors absorbed the negative take. That was a far steeper fall than the 0.3% slide of the S&P 500 (SNPINDEX: ^GSPC) that trading session. Bearish on Summit Well before market open that day, Leerink Partners' Daina Graybosch initiated coverage on Summit stock. This wasn't a positive appraisal, as the analyst flagged it with an underperform (read: sell) recommendation and a price target of $12 per share. That level is nearly 40% below Summit's most recent closing price. According to reports, Graybosch focused on ivonescimab, the high-profile cancer drug that Summit has licensed from China-based peer Akeso for jurisdictions outside the large Asian country. Despite good results in a recent head-to-head clinical study against Merck 's Keytruda, the analyst doesn't believe ivonescimab -- if approved in countries covered by Summit's license -- will grab enough market share to justify Summit's rather high valuations as a stock. She also believes that, as it's not the first drug of its kind, ivonescimab will face higher hurdles for clinical success, approval, and sales. It will be all about ivonescimab Like many biotech stocks, Summit's share price has been quite the seesaw, largely on ivonescimab developments. While I think Graybosch's assessment of its prospects are realistic, many types of cancer present large addressable markets, and I wouldn't necessarily count out Summit on the basis of those valuations. Much will depend, of course, on the drug's clinical trials in this part of the world. Should you invest $1,000 in Summit Therapeutics right now? Before you buy stock in Summit Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Summit Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor 's total average return is996% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
8 hours ago
- Globe and Mail
Fortrea Names Anshul Thakral Chief Executive Officer
DURHAM, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the 'Company'), a leading global contract research organization (CRO), today announced that Fortrea's Board of Directors (the 'Board') named Anshul Thakral as Fortrea's CEO, effective August 4, 2025. He was also appointed to serve as a director on the Company's Board, effective as of that date. Thakral succeeds Interim CEO, Peter M. Neupert, who will remain as chairman of the board. Thakral brings more than 20 years of experience in life sciences as an executive and commercial leader, advisor and entrepreneur. He will focus on executing the Company's transformation plan and sharpening Fortrea's focus on profitable growth. Further, he will oversee additional value creation efforts for customers, employees and shareholders. 'Anshul is an exceptional leader with extensive life sciences experience, deep familiarity with the CRO industry, a commitment to innovation and a proven record of building companies and growing revenue,' said Neupert. 'His strong business development capabilities, commercial insights and relentless focus on customer engagement make him ideally suited to lead Fortrea. Further, he also shares the Company's commitment to modernizing the clinical trials process and combining the best talent, science and technology to effectively and efficiently respond to changing customer and patient needs. We are delighted to welcome Anshul to Fortrea as we seek to capitalize on the significant growth opportunities we see ahead and meet our customers' needs.' 'Since its founding, the Fortrea team has earned a strong reputation for leading with science and creating a differentiated customer experience,' said Thakral. 'I share the team's passion for customers and the patients they serve, and I'm honored to take the reins at this pivotal moment. It is an exciting opportunity to lead the organization as it continues to deliver flexible and agile drug development solutions that accelerate the delivery of life-changing treatments to patients. I'm confident this company can execute on its patient and customer-focused mission while delivering profitable growth, which ultimately delivers value for shareholders.' About Anshul Thakral Thakral joins Fortrea from Launch Therapeutics, a company he co-founded at which he served as CEO. Previously, he held several executive leadership roles at PPD, a leading CRO, including chief commercial officer and executive vice president of Peri- and Post-Approval Services. He led PPD Biotech, which contributed to PPD's growth. Prior to PPD, Thakral ran the global life sciences business unit at Gerson Lehrman Group and served as an Associate Principal at McKinsey & Company in the healthcare practice. He currently serves on the board of directors of TriNetX, Saama Technologies and Orsini Specialty Pharmacy. He earned his B.S. and M.S.E. in Biomedical Engineering from Johns Hopkins University and his MBA from the Wharton School at the University of Pennsylvania. About Fortrea Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at and follow us on LinkedIn and X (formerly Twitter). Cautionary Statement Regarding Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, the Company's growth opportunities. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as 'guidance,' 'expect,' 'assume,' 'anticipate,' 'intend,' 'plan,' 'forecast,' 'believe,' 'seek,' 'see,' 'will,' 'would,' 'target,' similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from the Company's expectations due to a number of factors, including, but not limited to, the following: the Company's ability to successfully implement its business strategies and execute its long-term value creation strategy; risks and expenses associated with the Company's international operations, tariff policies, trade sanctions and other trade restrictions and currency fluctuations; the Company's customer or therapeutic area concentrations; any further deterioration in the macroeconomic environment or further changes in government regulations and funding, which could lead to defaults or cancellations by the Company's customers; the risk that the Company's backlog and net new business may not be indicative of the Company's future revenues and that the Company might not realize all of the anticipated future revenue reflected in the Company's backlog; the Company's ability to generate sufficient net new business awards, or the possibility that net new business awards are delayed, terminated, reduced in scope, or fail to go to contract; if the Company underprices its contracts, overruns its cost estimates, or fails to receive approval for, or experiences delays in documentation of change orders; and other factors described from time to time in documents that the Company files with the SEC. For a further discussion of the risks relating to the Company's business, see the 'Risk Factors' Section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the "SEC"), as such factors may be amended or updated from time to time in the Company's subsequent periodic and other filings with the SEC, which are accessible on the SEC's website at These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in the Company's filings with the SEC. All forward-looking statements are made only as of the date of this release and the Company does not undertake any obligation, other than as may be required by law, to update or revise any forward-looking statements to reflect future events or developments. Contacts:
Globe and Mail
11 hours ago
- Globe and Mail
Preclinical CRO Market to Hit USD 12.21 Billion by 2032 with 8.82% CAGR
According to a recent report by Coherent Market Insights, the global Preclinical CRO Market is estimated to be valued at USD 6.76 billion in 2025 and is expected to reach USD 12.21 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.82% from 2025 to 2032. Rising demand for outsourcing preclinical research activities, a growing number of pharmaceutical and biotech businesses, and a growing emphasis on drug discovery and development help to explain the market's notable expansion. Global Preclinical CRO Market Key Takeaways Registering a CAGR of 8.82%, the global preclinical CRO market size is forecast to expand from USD 6.76 Bn in 2025 to USD 12.21 Bn by 2032. By service, bioanalysis and DMPK segment is expected to account for a revenue of USD 2.40 Bn in 2025. Based on type, PDX models category is anticipated to account for more than three-fifths of the global preclinical CRO market share in 2025. Small animal model segment is set to dominate the target industry, accounting for about USD 3.92 Bn in 2025. As per Coherent Market Insights' latest preclinical CRO market analysis, North America is projected to hold nearly 2/3 of the global market revenue share in 2025. This is attributable to increasing funding in research and development, favorable government support, and growing demand for quality preclinical CRO services. Asia Pacific is poised to experience fastest growth during the forecast period, owing to rising prevalence of chronic diseases and expanding pharmaceutical and biotechnology sectors. Rising Demand for Novel Pharmaceuticals and Biologics Fueling Market Growth Coherent Market Insights' latest preclinical CRO market research highlights key factors driving industry growth. One such prominent growth driver is the increasing demand for novel pharmaceutical and biological products. The global burden of chronic and infectious diseases is growing, creating an urgent need for new, effective therapeutic solutions. This, in turn, is expected to increase demand for preclinical contract research organizations (CROs) as they play a critical role in the early-stage development and safety assessment of these novel therapies. Increasing complexity and cost of developing new drugs, especially gene therapies and cell therapies, is posing a challenge for pharmaceutical and biotechnology companies. To address this, they outsource preclinical research to specialized CROs. For instance, a survey by the Biotechnology Innovation Organization (BIO) found that 74% of 124 U.S. biopharma companies contract Chinese CDMO/CMO for preclinical and clinical services. Thus, rising demand for novel therapies will continue to boost preclinical CRO market growth. Purchase Now Up to 25% Discount on This Premium Research Report: High Cost of Preclinical Studies Restraining Market Growth The future preclinical CRO market outlook looks promising. This is due to rising demand for preclinical CRO services in pharmaceutical and biotech sectors. However, expensive nature of preclinical studies is negatively impacting the preclinical contract research organization (CRO) market growth to some extent. Preclinical research, including animal studies as well as toxicology testing, is quite expensive. This deters smaller biotech firms from outsourcing to CROs, thereby limiting overall preclinical CRO market demand. Growing Trend of Outsourcing R&D Activities Creating New Growth Prospects New drug research and development is a complex and costly task. This is where preclinical CROs step in. Many pharmaceutical and biotechnology companies are outsourcing their research to preclinical Contract Research Organizations (CROs) to Access specialized expertise Reduce costs Save time And focus on core competencies High-cost of in-house testing is encouraging pharmaceutical and biotechnology companies to outsource to contract research organizations. Preclinical CROs provide specialized expertise, infrastructure, and services during the early stage of drug development. They have the tendency to significantly lower overall drug development costs. For instance, according to Frost & Sullivan research results revealed by Avance Clinical at BIO24, biotech companies can reduce costs by over 30% and halve start-up times with CROs that have in-house scientific and regulatory affairs. More and more companies are expected to opt for outsourcing to preclinical CROs to cut costs and accelerate the transition to clinical trials. This growing trend of outsourcing in the pharmaceutical and biotechnology sectors will likely create lucrative growth opportunities for preclinical CROs. Impact of AI on the Preclinical CRO Market Artificial intelligence (AI) is revolutionizing the preclinical CRO market by enhancing efficiency, accuracy, and speed in drug discovery and development processes. It streamlines processes through data analysis, prediction, and automation. AI-driven tools enable advanced data analysis, predictive modeling, and automation of routine tasks. As a result, they help reduce the time and cost associated with preclinical testing. These tools enable CROs to deliver more reliable and comprehensive results, thereby accelerating the path to clinical trials. BenchSci, a prominent global leader in AI solutions for drug discovery, has made significant strides in this area. In January 2023, the company launched ASCEND, an end-to-end Software as a Service (SaaS) platform aimed at expediting the preclinical phase of drug development pipelines. ASCEND uses artificial intelligence to derive biological insights into the foundational aspects of diseases. By doing so, it enhances efficiency and accuracy of preclinical research. Rising adoption of such advanced technologies will likely boost the preclinical CRO market value. Emerging Preclinical CRO Market Trends Rising demand for toxicology testing is expected to create revenue-generation streams for preclinical CROs during the forecast period. There is a rising emphasis on safety, especially in oncology and immunology drugs. This will create need for toxicology services offered by CROs. The preclinical CRO industry is also witnessing a rapid shift towards integrated services, ranging from drug discovery to IND filing. This growing popularity of end-to-end solutions is set to play a key role in boosting revenue growth. Top CROs are focusing on employing artificial intelligence, machine learning, and advanced imaging technologies to enhance accuracy and speed of preclinical testing. This will allow them to attract more and more customers, thereby fueling growth of preclinical CRO market. Automated systems are also being used to rapidly screen thousands of compounds for biological activity. This leads to quicker results and reduces human errors. Similarly, 3D cell culture and organ-on-a-chip systems are becoming popular among CROs. Analyst's View ' The global preclinical CRO market is poised for rapid growth, owing to rising prevalence of chronic disease, increasing investments in new drug research and development, and growing trend of outsourcing in pharmaceutical and biotechnology sectors,' said senior analyst Komal Dighe. Current Events and Their Impact on the Preclinical CRO Market Event Description and Impact Rise in AI-Powered Preclinical Platforms (e.g., Insilico Medicine's Preclinical AI Suite) Description: Companies like Insilico Medicine and BenchSci introduced AI-powered platforms for preclinical testing in 2023-2024. Impact: CROs using AI tools achieve up to 30% faster screening and lower failure rates, boosting competitiveness and client appeal. U.S. FDA's 2025 Focus on Animal-Free Preclinical Models Description: FDA announced new guidance in early 2025 to promote and encourage the use of alternative, non-animal testing methods like organ-on-chip and in silico models in preclinical research. Impact: CROs offering innovative, ethical, and animal-free testing models are well-positioned to gain regulatory and client preference, enabling faster IND approvals. Competitor Insights Key companies listed in preclinical CRO market report: - Charles River Laboratories - WuXi AppTec - Covance (Labcorp) - Medpace - Syneos Health - ICON plc - PPD (Part of Thermo Fisher Scientific) - BioReliance (Merck KGaA) - Evotec SE - KCR - Charles River - Inotiv - Parexel International - Harlan Laboratories - Toxikon Key Developments In April 2025, CAS collaborated with Charles River Laboratories to strengthen its commitment to CRO scientific innovation. This new initiative is intended to accelerate drug discovery innovation. In June 2024, Novotech launched Early Phase Strategic Delivery Unit (EP SDU) for Biotechs for early phase clinical development. The new unit is intended to help the company's biotech clients expedite their early phase work before expanding into later one. Market Segmentation Service Insights (Revenue, USD Bn, 2020 - 2032) Bioanalysis and DMPK studies In vitro ADME In-vivo PK Toxicology Testing GLP Non-GLP Compound Management Process R&D Custom Synthesis Others Chemistry Medicinal Chemistry Computation Chemistry Safety Pharmacology Others Type Insights (Revenue, USD Bn, 2020 - 2032) Patient-Derived Organoid (PDO) Models Patient-Derived Xenograft (PDX) Models Animal Model Insights (Revenue, USD Bn, 2020 - 2032) Small Animal Model Large Animal Model Model System Insights (Revenue, USD Bn, 2020 - 2032) In Vivo In Vitro Application Insights (Revenue, USD Bn, 2020 - 2032) Oncology Neurology Cardiology Infectious Diseases Metabolic Disorders Others End Users Insights (Revenue, USD Bn, 2020 - 2032) Biopharmaceutical Companies Government and Academic Institutes Medical Device Companies Research Institutes and Universities Others Regional Insights (Revenue, USD Bn, 2020 - 2032) North America U.S. Canada Latin America Brazil Argentina Mexico Rest of Latin America Europe Germany U.K. Spain France Italy Russia Rest of Europe Asia Pacific China India Japan Australia South Korea ASEAN Rest of Asia Pacific Middle East GCC Countries Israel Rest of Middle East Africa South Africa North Africa Central Africa Get Customization on this Report: About Us: Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
